Clearmind Medicine Doses First Patient in Alcohol Use Disorder Trial
Ticker: CMND · Form: 6-K · Filed: Jun 30, 2025 · CIK: 1892500
Sentiment: bullish
Topics: clinical-trial, drug-development, alcohol-use-disorder
TL;DR
Clearmind (CMND) dosed first patient in AUD trial with CMND-100. HUGE step.
AI Summary
Clearmind Medicine Inc. announced on June 30, 2025, that it has dosed the first participant with its CMND-100 treatment in a clinical trial for Alcohol Use Disorder. This marks a significant milestone as the first time this treatment has been administered to a human subject in a trial setting.
Why It Matters
This event signifies the initiation of human testing for Clearmind's novel treatment for Alcohol Use Disorder, potentially offering a new therapeutic option for millions affected by this condition.
Risk Assessment
Risk Level: medium — Clinical trial initiation carries inherent risks, including potential lack of efficacy, safety concerns, and regulatory hurdles.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Registrant
- CMND-100 (drug_candidate) — Treatment being tested
- Alcohol Use Disorder (medical_condition) — Indication for the clinical trial
- June 30, 2025 (date) — Date of press release and filing
FAQ
What is the primary purpose of the CMND-100 treatment?
The CMND-100 treatment is being investigated for its potential to treat Alcohol Use Disorder.
When was the first participant dosed with CMND-100?
The first participant was dosed on June 30, 2025.
What type of clinical trial is this for CMND-100?
This is a groundbreaking clinical trial for Alcohol Use Disorder, marking the first time a participant has been dosed with the CMND-100 treatment.
What is the filing form and date?
The filing is a Form 6-K, filed on June 30, 2025.
What is Clearmind Medicine Inc.'s fiscal year end?
Clearmind Medicine Inc.'s fiscal year ends on October 31.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 30, 2025 regarding Clearmind Medicine Inc. (CMND).